Andrew Gengos, President & CEO, Director at ImmunoCellular Therapeutics, holds 238.33K shares in ImmunoCellular Therapeutics (Ticker: IMUC), holds ― shares in Synlogic (Ticker: SYBX), holds ― shares in Cyteir Therapeutics (Ticker: CYT).
What is the percentage of profitable transactions made by Andrew Gengos?
The percentage of profitable transactions made by Andrew Gengos is 17%.
What is the average return per transaction made by Andrew Gengos?
The average return per transaction made by Andrew Gengos is -12.10%.
What stocks does Andrew Gengos hold?
Andrew Gengos holds: IMUC, SYBX, CYT, ATHA stocks.
What was Andrew Gengos’s latest transaction?
Andrew Gengos latest transaction was an Uninformative Sell of $6.73K.
What was Andrew Gengos's most profitable transaction?
Andrew Gengos’s most profitable transaction was an Informative Sell of ATHA stock on January 8, 2024. The return on the trade was 79.20%.
What is Andrew Gengos's role in ImmunoCellular Therapeutics?
Andrew Gengos's role in ImmunoCellular Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.